L-Arginine and Reduced Neopterin Levels

Doses used in studies

g/day: 20 (median 20, IQR 20–20) — 1 study

Time to effect

Median: 7 days · IQR 7 days–7 days · Range 7 days–7 days — Reported in 1 of 1 study

1 of 1 paper

Efficacy of l-Arginine treatment in patients with HTLV-1-associated neurological disease.

2022-12-22
Clinical Trial · n = 20
Annals of clinical and translational neurology 10(2)
- Satoshi Nozuma
- Eiji Matsuura
- Yuichi Tashiro
- Ryusei Nagata
- Masahiro Ando
- Yu Hiramatsu
- Yujiro Higuchi
- Yusuke Sakiyama
- Akihiro Hashiguchi
- Kumiko Michizono
- Keiko Higashi
- Toshio Matsuzaki
- Daisuke Kodama
- Masakazu Tanaka
- Yoshihisa Yamano
- Takashi Moritoyo
- Ryuji Kubota
- Hiroshi Takashima

PubMed: 36547017
DOI: 10.1002/acn3.51715

3 Insights on

Reduced Neopterin Levels

Moderate evidence
Clinical

improvement in inflammatory markers in cerebrospinal fluid (CSF)... and in neopterin concentration in CSF (-2.1 pmol/mL, 95% CI -3.8 to -0.5; P = 0.01)

Effect: Beneficial
Effect size: Small
Significant: Yes
Dose: 20 g/day